Moxifloxacin, an 8-methoxy quinolone, is an important drug in the treatment of multidrug-resistant tuberculosis and is being investigated in novel drug regimens with pretomanid, bedaquiline, and pyrazinamide, or rifapentine, for the treatment of drug-susceptible tuberculosis. Early results of these studies are promising. Although current evidence does not support the use of moxifloxacin in treatment-shortening regimens for drug-susceptible tuberculosis, it may be recommended in patients unable to tolerate standard first-line drug regimens or for isoniazid monoresistance. Evidence suggests that the standard 400-mg dose of moxifloxacin used in the treatment of tuberculosis may be suboptimal in some patients, leading to worse tuberculosis treatment outcomes and emergence of drug resistance. Furthermore, a drug interaction with the rifamycins results in up to 31% reduced plasma concentrations of moxifloxacin when these are combined for treatment of drug-susceptible tuberculosis, although the clinical relevance of this interaction is unclear. Moxifloxacin exhibits extensive interindividual pharmacokinetic variability. Higher doses of moxifloxacin may be needed to achieve drug exposures required for improved clinical outcomes. Further study is, however, needed to determine the safety of proposed higher doses and clinically validated targets for drug exposure to moxifloxacin associated with improved tuberculosis treatment outcomes. We discuss in this review the evidence for the use of moxifloxacin in drug-susceptible tuberculosis and explore the role of moxifloxacin pharmacokinetics, pharmacodynamics, and drug interactions with rifamycins, on tuberculosis treatment outcomes when used in first-line tuberculosis drug regimens.
Tuberculosis (TB) ranks alongside human immunodeficiency virus (HIV) as a leading cause of death worldwide. 1 There were an estimated 10.4 million cases of TB in 2015, approximately 1.1 million of whom were coinfected with HIV. The African Region had 26% of the world's TB cases in 2015. 1 South Africa is 1 of the highest TB-and HIV-burdened countries in the world, 1 with HIV threatening TB treatment cure and completion rates, which in turn contribute to a high burden of multidrug-resistant (MDR) TB. [2] [3] [4] The current standard 6-month drug regimens for drug-susceptible TB are highly effective; however, challenges such as increasing drug resistance, HIV coinfection, poor treatment adherence, drug interactions, toxicity, or pharmacokinetic variability may result in suboptimal treatment outcomes. 5 The development of safe and effective TB drug regimens that shorten the time to sputum culture conversion, improve cure and treatment completion rates, and reduce morbidity, mortality, and relapse is critical. 5 Fluoroquinolones, including moxifloxacin, are highly active against Mycobacterium tuberculosis (MTB) 6 and are currently recommended in World Health Organization (WHO) and South African National Treatment guidelines for the treatment of multidrug-resistant TB. 7, 8 Furthermore, moxifloxacin may be recommended for treatment in drug-susceptible TB when 1 of the first-line TB drugs is not tolerated or for isoniazid monoresistance. [8] [9] [10] Several drug regimens recently tested or currently in clinical trials for both drug-susceptible and MDR TB include moxifloxacin in treatment-shortening or novel drug combinations. [11] [12] [13] [14] Moxifloxacin is being investigated in novel treatmentshortening regimens in combination with pretomanid or bedaquiline and pyrazinamide for drug-resistant and -susceptible TB 5, 11 and with high-dose rifapentine in the TB trials consortium study 31(NCT02410772) for drug-susceptible TB.
Evidence from mouse studies suggesting that moxifloxacin-containing regimens may reduce time to eradication of MTB by 2 months 15, 16 informed the design of phase 2 and 3 clinical trials investigating the ability of moxifloxacin-containing regimens to reduce the duration of TB treatment. 12, 13, [17] [18] [19] [20] [21] The REMox and RIFAQUIN clinical trials testing moxifloxacin in drug regimens for drug-susceptible TB found that these regimens resulted in faster sputum culture conversion but failed to improve clinical outcomes for relapse or treatment failure when treatment was shortened to 4 months in sputum smear-positive patients compared to standard 6-month regimens. 12, 13 Reasons for the disappointing outcomes of these studies have been explored in recent expert reviews, editorials, and studies. [22] [23] [24] [25] [26] [27] [28] The mouse model of TB and MTB cultured in the laboratory do not fully represent the course of human infection. 29, 30 Moreover, the 8-week sputum culture conversion end point used in earlier studies is not as predictive of relapse as was thought previously. 23 Several other factors may have contributed to differences in patient outcomes. These include disease severity, HIV coinfection, poor adherence, and reinfection. In addition, inadequate moxifloxacin concentrations, when the drug is given as part of treatment shortening regimens have been proposed as a contributing factor. [22] [23] [24] [25] 27, 28 Accumulating evidence suggests that adequate drug concentrations in plasma and sites of infection are necessary for optimizing TB treatment outcomes. [31] [32] [33] [34] [35] The optimal dose of moxifloxacin for the treatment of TB has not been clearly defined in humans. First, there is evidence that the current dose of 400 mg may lead to subtherapeutic plasma and tissue concentrations 32, 36 and the potential for an increased risk of treatment failure, relapse, or acquired drug resistance in some patients based on a study using a preclinical model of TB. 32 Second, plasma concentrations of moxifloxacin, are decreased by up to 31% when it is coadministered with rifamycins. [37] [38] [39] [40] [41] It is unclear whether this drug-drug interaction contributed to the clinical outcomes of the REMox and RIFAQUIN studies. Third, recent studies using matrix-assisted laser desorption/ionization mass spectrometry imaging found that moxifloxacin has heterogeneous distribution into lung tissues and granulomatous lesions with concentrations in these lesions higher than in plasma. Although moxifloxacin was shown to distribute well into the cellular regions of lesions, accumulation in the caseum, where persistent bacilli may be sequestered, is poor, particularly at lower than therapeutic concentrations. 24, 42 Therefore, higher doses of moxifloxacin at 600 mg to 800 mg have been suggested to achieve optimal drug exposure for therapeutic efficacy in some patients. 32, 36, 43 Safety data for these doses are, however, limited, although studies in patients with TB meningitis using 800-mg doses of moxifloxacin did not report significant safety issues. 44, 45 In this review we discuss the use of moxifloxacin in the treatment of drug-susceptible TB when it is substituted for or added to standard first-line drug regimens or when used in novel treatment-shortening regimens. In addition, we focus on the potential impact of pharmacokinetic (PK), pharmacodynamic (PD), and drug interaction studies investigating rifamycin coadministration on moxifloxacin drug exposure and TB treatment outcomes.
Methods/Search Criteria
We conducted a literature search in PubMed, using "moxifloxacin" or "fluoroquinolone" as Medical Subject Headings terms in combination with, "tuberculosis/TB," "pharmacokinetics/PK," "pharmacodynamics/PD," "minimum inhibitory concentration/MIC," "resistance," "early bactericidal activity/EBA," or "pharmacogenetics." Randomized controlled trials investigating moxifloxacin for treatment of drugsusceptible MTB, where moxifloxacin was substituted in or added to standard first-line TB drug regimens or was tested in shorter novel drug regimens were considered. All studies including relevant animal or in vitro data that demonstrate moxifloxacin PK, PD, or efficacy were included. Although this review focuses on drug-susceptible TB, studies that report on both drug-susceptible and MDR TB and those in MDR TB that provide information on moxifloxacin PK, PD, or efficacy were also included. We excluded studies testing moxifloxacin for infections other than MTB. The main outcomes of interest were efficacy of moxifloxacin (time to sputum culture conversion at month 2, relapse, treatment failure, or death) in the treatment of drugsusceptible TB and the PK of moxifloxacin when used alone or in combination with other TB drug therapy in healthy volunteers or patients with TB.
Results
Pharmacokinetics, Pharmacodynamics, and Efficacy of Moxifloxacin for Treatment of Drug-Susceptible TB
Mechanism of Action and Activity of Moxifloxacin Against
Mycobacterium tuberculosis. Moxifloxacin, an 8-methoxy fluoroquinolone, is bactericidal with activity against Gram-positive and Gram-negative bacteria including MTB. 46, 47 The bactericidal action occurs by binding to the topoisomerase enzymes II (DNA gyrase) and thus preventing replication, transcription, and repair of bacterial DNA. 48 Lethal action of the fluoroquinolones, including moxifloxacin, is suggested to occur through 2 steps, formation of bacteriostatic quinolone-gyrase-DNA complexes followed by chromosome fragmentation. 49, 50 A central feature of TB is the tendency of MTB to enter a dormant state in which the bacterium is likely to exhibit low susceptibility to chemotherapeutic agents. 51 Moxifloxacin has been shown to have a unique ability to kill mycobacteria in the absence of ongoing protein synthesis or while in a dormant state, which is important for the eradication of the TB infection and prevention of relapse. 49, 50 Pharmacokinetics Absorption. Moxifloxacin is easily and rapidly absorbed after oral administration. Bioavailability of moxifloxacin following oral dosing exceeds 90%. 52 Drug Distribution. Poor long-term treatment outcomes in some patients despite clearance of MTB determined by negative sputum cultures suggest that the bacilli may persist in lung cavities, granulomas, caseum, abscesses, and other lung or tissue lesions that may not be accessible to anti-TB drug therapy. 12, 13 It is clear that the efficacy of drugs used in the treatment of TB may be affected by their ability to distribute adequately to sites of action in lung tissue, epithelial lining fluid, macrophages, granulomas, caseum, or necrotic lesions. Moxifloxacin is widely distributed, with some tissue concentrations reported in excess of plasma levels. 24, 42, 53, 54 Concentrations in epithelial lining fluid, lung tissue, alveolar macrophages, and bronchial mucosa exceed the minimum inhibitory concentration (MIC) values for activity against MTB and values for the WHO-defined critical concentration of 2.00 mg/L. 24 However, recent studies in a rabbit model of TB and patients undergoing lung resection surgery using matrix-assisted laser desorption/ionization mass spectrometer imaging found that although moxifloxacin concentrations in lesions are approximately 3 times higher than in plasma, and the drug distributes efficiently to lung tissue, lung epithelial fluid, and the periphery of granulomas, it does not accumulate as efficiently in the caseum, where slowly replicating persistent MTB bacilli may be sequestered (Figure 1) . 24, 42 Furthermore, the study in patients undergoing lung resection surgery determined the concentrations of drugs and metabolites in homogenized lesions, relative to the aerobic MIC and the minimum anaerobic cidal concentration, a measure of drug activity against bacilli persisting in necrotic lesions where anaerobic conditions prevail. 24 Moxifloxacin, in contrast to isoniazid, rifampicin, and pyrazinamide, was shown to be consistently present at significantly higher concentrations in lesions than in plasma, above the MIC in all lesion homogenates and at or above the minimum anaerobic cidal concentration in 38% of the lesions, indicating that it might reach nongrowing persistent bacilli at therapeutic concentrations. 24 These factors may have contributed to the failure to shorten TB treatment and especially to the high relapse rate found in recent studies using moxifloxacin, 12, 13 further exacerbated by suboptimal drug concentrations achieved in some patients due to intraindividual variability in PK parameters, poor adherence or drug absorption, drug interactions (rifamycins), and or genetic variability. These studies also investigated the distribution of rifampicin and pyrazinamide into the caseous lesions and found that these drugs distributed evenly and achieved higher concentrations in the caseum when compared to moxifloxacin, findings that support treatment-shortening ability of rifampicin and pyrazinamide. 24, 42 Moxifloxacin has good penetration into cerebrospinal fluid and has been used effectively with rifampicin for the treatment of drug-susceptible TB meningitis at higher doses of 800 mg; however, these higher doses were not found to be significantly associated with improved treatment outcomes. 44, 45 Metabolism and Drug Transport. Moxifloxacin is metabolized in the liver via glucuronide and sulfate conjugation by cytosolic enzymes glucuronosyltransferase and sulfotransferase. 55 The major human uridine diphosphate (UDP)-glucuronosyltransferases (UGTs) responsible for formation of the glucuronide metabolite are UGT1A1, UGT1A3, and UGT1A9 (UGT1A1 being the main isoform). Moxifloxacin is a substrate of p-glycoprotein, and the drug transporter protein plays an important role in its absorption, distribution, and elimination. 56, 57 The cytochrome P450 (CYP450) enzyme system is not involved in the metabolism of moxifloxacin, nor is it affected by the drug. 58 Neither moxifloxacin nor its metabolites inhibit the CYP450 enzymes. Similarly, moxifloxacin was shown not to be an inhibitor of any of the major human UDP-glucuronosyltransferases. The sulfate conjugate accounts for 38% of the oral dose and is excreted in feces; about 14% of an oral dose is converted to the glucuronide conjugate and is excreted in urine. 59 Peak plasma levels of the sulfate and glucuronide metabolites are <10% and about 40% those of the parent drug, respectively. Overall, about 45% of an oral dose is excreted unchanged as parent drug, and about 51% as known sulfate and glucuronide metabolites, which are biologically inactive.
Drug and Food
Interactions. Coadministration with food may slightly prolong time to maximum concentration and may reduce the maximum serum concentration (C max ) by 16%; these effects are thought to be insignificant, and moxifloxacin may therefore be administered with or without food. 60 Few clinically Iron-or zinc-containing multivitamin supplements, magnesium-or aluminum-based antacids, and buffered didanosine should be dosed at least 2 hours before or after moxifloxacin. This may be challenging in patients with HIV coinfection, where multivitamin and iron supplements, in addition to antiretroviral therapy (ART), and drugs for TB and other treatment for opportunistic infections are prescribed. Drugs that inhibit or induce p-glycoprotein may also result in altered moxifloxacin pharmacokinetics. 63 These include cotrimoxazole, phenytoin, nifedipine, rifampicin, midazolam, ketoconazole, erythromycin, amiodarone, and mefloquine.
A recent study found a significant interaction with efavirenz, in which oral clearance of moxifloxacin was increased by 42%, resulting in an approximately 30% reduction in moxifloxacin drug concentrations when it was coadministered with efavirenz. 64 The significant drug interaction found between moxifloxacin and efavirenz-based ART in HIV-coinfected patients has not been previously described. Although this finding needs validation in other studies, it remains concerning, given the high HIV-TB coinfection rates in many TB endemic settings where the ART backbone is efavirenz. These findings have direct implications for studies evaluating novel drug regimens containing moxifloxacin and for the use of moxifloxacin in nonstandard treatment regimens for both drug-susceptible and drugresistant TB.
Interaction With Rifamycins. The rifamycins including rifampicin and rifapentine induce the activity of the phase 2 drug-metabolizing enzymes glucuronosyltransferase and sulfotransferase and the drug transporter protein p-glycoprotein. 65, 66 Moxifloxacin is a substrate of these enzymes and the drug transporter, and rifamycin induction results in altered moxifloxacin pharmacokinetics. The findings of several studies investigating the potential interaction between moxifloxacin and the rifamycins either in healthy individuals or in patients with TB [37] [38] [39] [40] [41] 64, 67 are summarized in Table 1 . All these studies demonstrate decreased plasma concentrations of moxifloxacin at steady state as a result of rifamycin coadministration. Area under the concentration-time curve (AUC) and C max reductions of 8% to 31% were reported. The variable results of these studies may be due to several factors including dose, dosing frequency, and type of rifamycin used, study design, and PK variability in TB patients vs healthy individuals. Studies investigating the impact of rifapentine and moxifloxacin coadministration found lower differences in moxifloxacin drug concentrations (8% to 17%), likely due to rifapentine exhibiting less potent induction of drug-metabolizing enzymes than rifampicin with the doses used and less frequent dosing. 41, 67 It is, however, possible that high daily doses of rifapentine may result in higher enzyme induction and lower moxifloxcin concentrations. Bioavailability studies conducted in healthy individuals and TB patients, using crossover or sequential study designs to limit interpatient variability and intensive PK sampling, found higher reductions in moxifloxacin AUC (27% to 31%) [38] [39] [40] in the presence of rifampicin compared to "real world" studies reporting high levels of heterogeneity between study groups compared and low sample sizes that may limit the generalizability of the findings. 37, 43 PK of moxifloxacin and other TB drugs may, however, differ in healthy individuals 39, 40 compared to patients with TB infection. 43, 68 Although the clinical relevance of the drug interaction between the rifamycins and moxifloxacin and impact on TB treatment outcomes need further investigation, moxifloxacin is known to have concentration-dependent activity, and lower concentrations will likely result in decreased drug activity and worse treatment outcomes in some patients.
Pharmacokinetic Data From Early Phase 1 Studies in
Healthy Volunteers. Moxifloxacin is well absorbed, with a bioavailability of approximately 90%. 52 Pharmacokinetics is linear, with C max and AUC increasing proportionally in the range of 50 to 800 mg for single doses and up to 600 mg once daily when dosing over 10 days. 69 Steady state is reached within 3 days. A single dose of 400 mg produces a C max of 2.5-4.5 mg/L, half-life of 11-15 h, AUC0-24 of 25-40 ug.h/mL and volume of distribution of 2.5-3.5 L/kg. Protein binding is about 50%. 70 T max is reached within approximately 1-3 hours.
58,71

Pharmacokinetics of Moxifloxacin in Patients With TB.
The pharmacokinetic parameters of moxifloxacin from clinical trials done in patients with tuberculosis or healthy individuals using tuberculosis drug regimens is summarized in Table 1 . [37] [38] [39] [40] [41] [43] [44] [45] 67, 68, [72] [73] [74] [75] [76] [77] The range of values for C max , AUC, and time to C max for moxifloxacin are in keeping with data from studies in healthy individuals, although the ranges were wide and more variable (Table 1) . 59, 70, 71 Importantly, moxifloxacin concentrations are consistently lower when the drug is coadministered with rifamycins. Extensive interindividual variability in moxifloxacin pharmacokinetic parameters is apparent, and the ranges for AUC and C max are wide. Doubling the moxifloxacin dose to 800 mg results in proportional increases in AUC and C max . Of note, most of the PK data from studies including moxifloxacin in tuberculosis treatment regimens were in HIV-uninfected individuals and in populations outside of Africa. Although HIV coinfection itself may lead to altered PK and lower concentrations of tuberculosis drugs, 78 little data exists on the potential interactions of moxifloxacin with antiretroviral treatment. One recent study reported a 42% increase in oral clearance of moxifloxacin, resulting in a 30% decrease in moxifloxacin AUC when coadministered with efavirenz-based antiretroviral treatment in patients with HIV coinfection. 64 African populations have shown high levels of host genetic diversity resulting in differences in tuberculosis disease susceptibility. 79 Furthermore, genetic diversity in drug-metabolizing ( and drug transport enzymes in the host leads to lower tuberculosis drug concentrations and variation in drug response.
80-82
Pharmacogenetics Genetic variation associated with single nucleotide polymorphisms, copy number variants, or insertions or deletions in genes coding for drug-metabolizing and transporter enzymes are increasingly recognized as factors that may affect tuberculosis drug exposure and result in variable pharmacokinetic parameters. 83 Moxifloxacin is metabolized via glucuronide and sulfate conjugation by cytosolic enzymes glucuronosyltransferase and sulfotransferase. The major human UGTs responsible for formation of the glucuronide metabolite are UGT1A1, UGT1A3, and UGT1A9. Although there are no previous published data on the polymorphisms of genes coding for UGT enzymes affecting moxifloxacin metabolism or pharmacokinetics in tuberculosis treatment, these are known to be highly polymorphic, leading to altered concentrations of other drugs and of moxifloxacin in healthy individuals. 84, 85 Moxifloxacin is a p-glycoprotein substrate, and limited data from 1 study investigating polymorphisms in the ABCB1 (MDR1) gene coding for this transport protein, found that the MDR 3435 CC polymorphism may affect the absorption of moxifloxacin. 40 ABCB1 also exhibits high functional variance, 86 and effects of polymorphisms in this drug transporter and genes coding for UGT enzymes on moxifloxacin pharmacokinetics need further investigation.
Pharmacodynamics
Many of the drugs currently being used in for the treatment of both drug-susceptible and MDR TB were developed when pharmacokinetics and pharmacodynamics of drugs were not evaluated during the development of drugs or regimens. Consequently, more than 45 years after its introduction, several studies are only now under way to determine the optimal dose of rifampicin for the treatment of tuberculosis. 87, 88 The optimal dose of moxifloxacin for the treatment of tuberculosis in humans has not been clearly defined. The PK-PD marker suggested to predict the clinical efficacy of fluoroquinolones, including moxifloxacin, is the total (protein-bound and unbound) AUC/MIC ratio, and ratios >100-125 and C max /MIC > 8-12 or >10, have been demonstrated in laboratory-based studies to be associated with better treatment outcomes, greatest bacteriological activity against MTB, and a decreased probability of resistance. 48, [89] [90] [91] A study using a novel PK infection model of tuberculosis reported doses of 800 mg as likely to achieve PK-PD (free/unbound AUC/MIC ratio) target attainment levels of >53, excellent MTB microbial kill, and complete suppression of the drug-resistant mutants. 32 The AUC/MIC target for moxifloxacin has, however, not yet been defined in humans with tuberculosis, and drug exposures linked to optimal treatment outcomes still need to be determined. To attain the proposed AUC/MIC target ratios of >100 to 125, AUC values 50 μg·h/mL and above must be achieved in patients where MICs are ࣘ0.25 to 0.50 mg/L. This AUC target is clearly not achieved in many tuberculosis patients using 400-mg doses, with AUCs as low as 8.5 and as high as 140 ug·h/mL, most, ranging between approximately 15 and 80 μg·h/mL and mean or median AUC values of about 30 μg·h/mL (Table 1 ). It is recognized that the effective treatment of tuberculosis requires drug regimens that include at least 3 or 4 effective drugs that work additively or synergistically to eradicate MTB, although the activity of each of these drugs within the regimen should be optimized to achieve better treatment outcomes.
Drug Resistance
Moxifloxacin is a fluoroquinolone, containing an 8-methoxy group and a hydrophobic diazabicyclononyl ring moiety with an S,S-configuration at the 7-position, which may reduce the ability of MTB to efflux the drug across the cell wall, thus lowering risk of efflux-mediated resistance in comparison to earlier generation fluoroquinolones, with MICs ranging between 0.12 and 0.50 mg/L. 92 Resistance to moxifloxacin and other fluoroquinolones occurs mainly as a result of point mutations within the quinolone resistance-determining region in DNA gyrase A (GyrA) and gyrase B (GyrB) genes. Although resistance to early-generation fluoroquinolones such as ofloxacin may not confer cross-resistance to newer, more potent fluoroquinolones such as moxifloxacin and levofloxacin, 93, 94 the most frequent quinolone resistance-determining region mutations are found at GyrA codons 90 (A90V), 91 (S91P), 94 (D94G, D94A, D94Y, D94N, and D94H), 48, 92, 95, 96 and double mutations in GyrA and GyrB have been reported. 92 Studies investigating the association between presence of mutations in clinical MTB isolates and MICs have shown variable results. Two studies in South Africa 92, 97 found that mutations at common codons 90 and 94 resulted in increases in MIC up to 2.00 mg/L, and studies in China and Thailand with similar findings also reported much higher MICs of up to 16.00 mg/L in a small percentage of patients with these and other mutations. 98, 99 A recent survey conducted in South Africa, Eastern Europe, and Asia found that resistance was between 0.9% and 14.6% for moxifloxacin when tested at 0.50 mg/L and much lower in all countries when tested at 2.00 mg/L. 94 The study also determined resistance to moxifloxacin among patients with rifampicin-sensitive and rifampicinresistant isolates. Among patients who were rifampicin sensitive (910 of 951), 0.5% (95%CI 0.0% to 1.1%) were resistant to moxifloxacin, and among those with rifampicin-resistant isolates (41 of 951), moxifloxacin resistance was 8.4% (95%CI 0.0% to 18.4%) when tested at 0.50 mg/L. Drug susceptibility testing for moxifloxacin commonly uses phenotypic methods and critical concentrations, defined as the lowest concentration of a drug that inhibits approximately 99% of wild-type strains lacking mechanisms of acquired or mutational resistance to the specific drug. 100 The WHO defined critical concentrations for moxifloxacin as 0.25 mg/L using mycobacterial growth inhibitor tube or 0.50 mg/L using solid media, 101 have recently been increased to 0.50 or 2.00 mg/L for both liquid and solid media, 102 based on evidence that moxifloxacin may have clinical efficacy in patients given that plasma drug concentrations achieved in most tuberculosis patients may exceed 2 mg/L. This may not, however, be the case in all tuberculosis patients or at all sites of action. The mutant prevention concentration, defined as the minimum concentration allowing no mutant recovery when >10
10 bacilli are applied to drug-containing agar, 103 is between 4.00 and 8.00 mg/L for moxifloxacin. These levels are less achievable in most patients with TB, which may lead to increased risk of acquired resistance in patients with low drug concentrations in plasma or sites of action and MICs ࣙ2.00 mg/L. 104 An additional concern is that the fluoroquinolones, including moxifloxacin, are used to treat a variety of bacterial infections 105 that present the risk of preexisting fluoroquinolone resistance and subsequent treatment failure if used in TB treatment. Moreover, in high-TB-burden countries such as South Africa, the risk of treating undiagnosed TB with moxifloxacin monotherapy increases the risk of emergent resistance.
Activity In Vitro, Murine Studies
Moxifloxacin is highly active against MTB in vitro. Minimum inhibitory concentrations (MIC90), defined as the lowest concentration of drug required to inhibit 90% of bacterial growth, are in the range of 0.06 to 0.25 mg/L, with moxifloxacin exhibiting greater inhibitory activity in comparison to ciprofloxacin, levofloxacin, and sparfloxacin 6 and similar activity to rifampicin. 47 Moxifloxacin has bactericidal activity comparable to isoniazid 111 and exhibits dose-dependent activity, postantibiotic effects, and additive sterilizing potential when combined with isoniazid and rifapentine or rifampicin. [112] [113] [114] Other fluoroquinolones such as gatifloxacin and high-dose levofloxacin (1 g) demonstrated similar findings with bactericidal activity comparable to isoniazid. 115 Studies found that addition of moxifloxacin to drug regimens containing rifampicin and pyrazinamide reduced the time to eradicate MTB from mouse lungs by up to 2 months 15 and prevented relapse for up to 6 months. 16 The 6-month treatment study was conducted in a murine model to evaluate the sterilizing activity with different regimens. Treatment with rifampicin, moxifloxacin, and pyrazinamide (RMZ) resulted in a 2.5-log greater reduction in colony-forming unit counts relative to rifampicin, isoniazid, and pyrazinamide at 2 months (P < .001). After 3 months of RMZ/rifampicin plus moxifloxacin, only 2 of 5 mice had positive lung cultures. In contrast, all 6 mice given rifampicin, isoniazid, and pyrazinamide/rifampicin plus moxifloxacin were still culture-positive at 4 months. These data suggest that the combination RMZ has greater sterilizing activity than the standard regimen and may be able to shorten the duration of therapy for human TB by 2 months or more. 16 Another study using 4 months of therapy with any of the rifampicin, isoniazid, and pyrazinamide-based regimens resulted in complete sterilization in all mice, whereas 4 months of therapy with the standard rifampicin, isoniazid, and pyrazinamide-based regimen resulted in a relapse rate of 42%. 15 These studies led to the design of phase 2 and 3 clinical trials investigating the ability of the fluoroquinolones to shorten the duration of tuberculosis treatment in patients with drug-susceptible TB.
Despite the improved bactericidal activity found in these studies, it must be noted that when rifampicin and moxifloxacin in combination were compared to these drugs used alone, it was shown in both the hollow fiber and mouse model of TB that the combination was efficacious for suppressing resistant organisms but may be antagonistic for cell kill. 116, 117 Rifampicin and moxifloxacin in combination showed similar efficacy in reduction of colony-forming unit count as moxifloxacin alone in the mouse model of infection. 117 The investigators of this study note an important consideration, that to achieve the dual goals of shortening the duration of therapy and suppressing resistance, the combination therapy must increase the rate of kill as well as suppress resistance. 117 This finding has not been fully investigated in human studies, although it is possible that this may have contributed to the poor outcomes of some of the phase 2 and 3 studies investigating the treatmentshortening ability of moxifloxacin for TB treatment.
Pyrazinamide contributes additional sterilizing activity beyond the first 2 months in moxifloxacincontaining regimens. 118 Moxifloxacin has also been investigated in novel drug regimens with pretomanid (PA 824) and pyrazinamide for the treatment of TB. A study conducted in the murine model of TB found that the combination of moxifloxacin, pretomanid, and pyrazinamide cured mice more rapidly than a standard regimen containing rifampicin, isoniazid, and pyrazinamide.
Human Studies
Early Bactericidal Activity (EBA) Studies. Moxifloxacin demonstrates early bactericidal activity, defined as the fall in log 10 colony-forming units (cfu) of MTB per milliliter sputum per day, comparable to isoniazid, [120] [121] [122] with 1 study reporting EBA of 0.53 log 10 cfu/day after 0.88 days for moxifloxacin compared to 0.77 log 10 cfu/day for isoniazid after 0.48 days (see Table 2 ). 122 Studies testing moxifloxacin in combination with isoniazid found no increase in bactericidal activity, although the combination was not antagonistic. 122 Moxifloxacin demonstrates EBA similar to other, newer-generation fluoroquinolones, gatifloxacin, and high-dose levofloxacin. 115 The mean 14-day EBA of pretomanid-moxifloxacinpyrazinamide (n = 13; 0.233 [SD 0.128]) was comparable to that of standard first-line treatment (n = 10; 0.140 [SD 0.094]). 123 Phase 2 and 3 Clinical Trials. Studies investigating the efficacy of moxifloxacin for the treatment of drugsusceptible TB, are summarized in Table 3 . Drug regimens used in these studies either replaced ethambutol or isoniazid with moxifloxacin, or added moxifloxacin to, the standard first line drug regimen or tested novel drugs, bedaquiline, or pretomanid with moxifloxacin and pyrazinamide. All studies included patients with sputum smear-positive TB, mainly HIV uninfected, and most studies reported 60% to 70% or greater cavitation at baseline. [11] [12] [13] [17] [18] [19] [20] [21] 76, 110, 124 Studies Reporting Proportion of Patients With Negative Sputum Culture at 8 Weeks. In studies in which moxifloxacin replaced ethambutol or isoniazid in the standard drug regimen, no statistically significant difference was found in sputum culture conversion at 8 weeks of treatment 17, 18, 76, 110, 124 except in 2 studies conducted in Brazil and India, which reported favorable activity for the moxifloxacin-containing regimens. 19, 21 However, moxifloxacin-containing regimens resulted in significantly higher proportions of sputum culture conversion at time points earlier than 8 weeks. 17, 18, 76, 124 A Cochrane review and meta-analysis 125 assessing the use of fluoroquinolones in drug-susceptible tuberculosis, including these earlier studies, 17, 76, 110 found insufficient evidence on whether addition or substitution of the fluoroquinolones (moxifloxacin, gatifloxacin, and levofloxacin) for ethambutol or isoniazid in the first-line regimen reduces death or relapse, or increases culture conversion at 8 weeks. One phase 2 study investigating g Unfavorable outcome based on primary efficacy end points for composite treatment failure and relapse. Safety (grade 3 or 4 adverse events) was not significantly different when compared across arms for all studies.
h All patients allocated to the 4 moxifloxacin regimens received the same daily treatment (RHZEM) for the first 2 months; the study combined the results of these regimens and compared them with the control regimen.
the efficacy of levofloxacin in shortening time to culture conversion when added to standard drug regimens found no improvement in treatment outcomes, and levofloxacin 125 was not moved forward into subsequent phase 3 treatment shortening trials testing efficacy of moxifloxacin and gatifloxacin regimens.
A study testing the novel combination of moxifloxacin, pretomanid, and pyrazinamide found this regimen to have superior bactericidal activity during the first 8 weeks of treatment compared with the standard of care of isoniazid, rifampicin, pyrazinamide, and ethambutol, when measured by the reduction in cfus of MTB per milliliter of sputum. 11 This regimen is now being tested in the phase 3 STAND trial (NCT02342886), and results of the study are expected in 2018.
Studies Reporting TB Treatment Failure, Relapse, or Death at 18 or 24 Months. Three treatment-shortening trials testing moxifloxacin-containing regimens of 4 months' duration compared to standard 6-month drug regimens for the treatment of drug-susceptible tuberculosis failed to demonstrate noninferiority of 4-month moxifloxacin regimens. 12, 13, 20 The findings of these studies were in keeping with previous reports of moxifloxacin regimens resulting in a more rapid decline in bacterial load and earlier sputum conversion; however, rates of relapse, treatment failure, or death were higher in the 4-month moxifloxacin arms compared to the standard 6-month regimens at 18 or 24 months of followup. The RIFAQUIN trial found high-dose rifapentine (1200 mg) and moxifloxacin once weekly as part of a 6-month treatment regimen to be as effective as the standard 6-month regimen. 13 This isoniazid-sparing regimen may have a role in settings with high levels of isoniazid resistance, although previous reports of impaired rifapentine efficacy and acquired drug resistance using lower doses in combination with isoniazid in HIV-infected patients may need further investigation when used in combination with moxifloxacin at higher doses. 126, 127 The disappointing results of these large, robust, and expensive phase 3 studies have been extensively reviewed in other reports. 23, 26, 27, 29, 30 In light of these findings questions have been raised regarding the reliability of the early mouse-model data that informed the design of the phase 2 and 3 treatment-shortening studies; however, 1 study that analyzed the relapse data from the mouse studies concluded that researchers may have overestimated the findings of these studies as well as those of the phase 2 clinical trials conducted. 26, 29 Inadequate moxifloxacin concentrations in plasma and sites of action have also been suggested as contributing factors for the poor outcomes shown. 24, 27 Safety Moxifloxacin is generally well tolerated. Most common adverse events in adults include gastrointestinal (nausea, diarrhea) and neurological (headache, dizziness) toxicities or arthralgia. Serious adverse events are rare and include tendon inflammation and rupture (particularly in elderly patients and in those treated concurrently with corticosteroids), seizures, anaphylaxis, skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis and antibiotic-associated colitis. 58, 106 Moxifloxacin has been shown to prolong the QT interval of the electrocardiogram in some patients by reversible and dose-dependent but weak blockage of the human Ether-à-go-go-Related Gene (hERG) potassium channels. For this reason higher doses of moxifloxacin should be used with caution. Some evidence from studies in TB meningitis where higher doses (600-800 mg) may be justified suggests that these may be safe when carefully monitored. 44, 45, 107 Moxifloxacin should be used with caution in patients on antiarrhythmic drugs and other drugs with known effects on QT prolongation, notably bedaquiline, also used in the treatment of tuberculosis. 108 A drug safety review of clinical data comparing safety and risk of adverse events in patients on moxifloxacin with similar comparator drugs found no significantly increased risk of adverse events with moxifloxacin. 109 Phase 2 or 3 studies conducted in patients with tuberculosis (Table 3) did not report any significant difference in the incidence of grade 3 or 4 adverse events between moxifloxacincontaining arms of the study and standard treatment regimens. 12, 13, [17] [18] [19] 21, 76, 110 In keeping with other non-TB studies, moxifloxacin significantly increased rates of nausea and GI upset and arthralgia compared to standard TB therapy. 17, 21, 110 The REMox study reported a nonsignificant reduction in incidence of hepatotoxicity for both of the experimental moxifloxacin-containing arms. 12 Moxifloxacin has been used as part of a "liversparing" regimen, in treatment of patients with TB.
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Conclusions
Studies of moxifloxacin-containing regimens for treatment of drug-susceptible TB have reported earlier sputum culture conversion, although current evidence does not support the use of moxifloxacin in treatmentshortening regimens. The RIFAQUIN trial found highdose rifapentine (1200 mg) and moxifloxacin once weekly as part of a 6-month treatment regimen to be as effective as the standard 6-month regimens. Moxifloxacin may be used in drug-susceptible TB if toxicity develops to first-line drugs or for INH monoresistance, with no additional safety concerns when compared to current first-line regimens, and remains an important drug for the treatment of MDR and extensively drugresistant TB. Higher bactericidal activity also suggests that moxifloxacin-containing regimens are at least as bactericidal as the current standard first-line regimens. Early results of studies using moxifloxacin in novel drug regimens are promising. PK is highly variable, and drug exposures achieved in plasma and sites of action, using a standard 400-mg dose, may not be optimal for clinical efficacy, preventing emergent resistance, or achieving the proposed PK-PD targets for clinical efficacy in all patients. Coadministration of rifamycins decreases moxifloxacin drug concentrations by up to 31%. Although the clinical relevance of this effect has not been evaluated, with moxifloxacin's concentration-dependent activity, lower concentrations are expected to result in decreased activity and potentially worse treatment outcomes in some patients. The potential to improve clinical outcomes by adjusting drug dosages to achieve therapeutic targets presents an important opportunity to optimize the current treatment strategies used and reduce the risk of emergent resistance.
Knowledge Gaps and Future Research
Clinically validated targets for drug exposure to moxifloxacin associated with improved TB treatment outcomes need to be defined. Despite limited resources for tuberculosis research, clinical trials testing the efficacy of new or repurposed TB drugs should include PK-PD studies that can fill knowledge gaps on effects of PK variability and drug interactions on drug exposures and treatment outcomes, in diverse patient populations and comorbidities. Specifically, the impact of HIV coinfection and ART co-treatment on moxifloxacin pharmacokinetics in high-HIV-burden settings needs investigation. Limited data are currently available on the effect of rifampicin coadministration in African patients. Safety data for dosing moxifloxacin at higher doses of 600 to 800 mg are limited, and some data will become available from the STREAM clinical trial testing moxifloxacin at 800 mg for MDR TB. 14 The effects of pharmacogenetic variation in relevant drugmetabolizing enzymes and drug transporter proteins on moxifloxacin PK parameters in tuberculosis treatment are an area for future research. Therapeutic drug monitoring is a standard clinical technique using plasma drug concentrations to guide dosing. Both use of drug concentration monitoring and adjustment of drug dosages in individual patients have been employed in certain TB treatment centers to make informed dosing decisions, especially in patients with poor treatment responses. As more data become available on optimizing TB treatment outcomes using therapeutic drug monitoring, it may become more widely used although its routine use in resource-constrained settings presents a challenge. Resources should be made available for future research in operational settings to include the use of cheaper innovative technology and less invasive methods in PK studies, such as dry blood spots, which have been clinically validated for moxifloxacin 128 and may be stored at room temperature, as well as MIC testing plates 129 to determine PK-PD parameters. 34 Furthermore, well-designed studies that will define clinically validated targets for moxifloxacin and other TB drugs are necessary. One study by Pasipanodya et al defined target thresholds of drug exposures for current first-line tuberculosis drugs that predicted poor treatment outcomes. 33 However, other similar studies that determine associations between drug exposures such as AUC adjusted for MIC (AUC/MIC ratio) and time to sputum culture conversion at 8 weeks, treatment failure, relapse, or days to positivity, using modeling or statistical analysis methods that are able to capture the complex usually nonlinear interactions among drug exposures and clinical and other factors predicting TB treatment outcomes are needed. 
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